Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

NCT06603376 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Carcinoma

Interventions

DRUG: FOLFIRI + Vemurafenib + Cetuximab
DRUG: FOLFIRI ± Bevacizumab

Sponsor

Shanghai Changzheng Hospital